These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24401641)

  • 1. Antiretroviral reduction: is it time to rethink the unthinkable?
    Colasanti J; Marconi VC; Taiwo B
    AIDS; 2014 Apr; 28(7):943-7. PubMed ID: 24401641
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)].
    ;
    Dtsch Med Wochenschr; 2009 Jan; 134 Suppl 1():S4-15. PubMed ID: 19172554
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status and challenges of antiretroviral research and therapy.
    Esté JA; Cihlar T
    Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral Therapy.
    Brock JB; Henderson H
    J Miss State Med Assoc; 2015 Jun; 56(6):166, 171-2. PubMed ID: 26242056
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiretroviral therapy: treatment-experienced individuals.
    Calvo KR; Daar ES
    Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir: after multiple antiretroviral treatment failure: another option.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18629967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 11. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic.
    Klibanov OM; Dolder CR; Assefa F; Ekwonu TJ
    AIDS Patient Care STDS; 2013 Apr; 27(4):205-7. PubMed ID: 23514132
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding.
    Fiore JR; Zoboli F; Di Stefano M; Faleo G; Fasano M; Santantonio TA
    AIDS; 2016 Apr; 30(7):1144-6. PubMed ID: 27028146
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.
    Boyd MA; Boffito M; Castagna A; Estrada V
    HIV Med; 2019 Mar; 20 Suppl 1():3-11. PubMed ID: 30724450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preconception antiretroviral therapy and birth defects: what is needed?
    Bulterys M; Berry RJ; Watts DH
    AIDS; 2014 Nov; 28(18):2777-80. PubMed ID: 25493603
    [No Abstract]   [Full Text] [Related]  

  • 17. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key Principles of Antiretroviral Pharmacology.
    Dionne B
    Infect Dis Clin North Am; 2019 Sep; 33(3):787-805. PubMed ID: 31395145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to antiretroviral drugs: a threat to the prevention and treatment of pediatric HIV infection.
    Krogstad PA
    J Infect Dis; 2007 May; 195(10):1393-5. PubMed ID: 17436216
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicities of antiretroviral therapy in children.
    Nwaobasi E; Oleske JM
    AIDS Read; 2006 Oct; 16(10):537-40, 544-6,549-50, 552-4. PubMed ID: 17096472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.